1 Suppression of influenza virus infection by rhinovirus interference at the

2 population, individual and cellular levels

- 3
- 4 Kin P Tao, PhD^{1,2,3,4}[†], Marc Chong, PhD⁵[†], Jason CS Pun, BSc^{1,2,3,4}, Joseph GS Tsun,
- 5 PhD^{1,2,3,4}, Samuel MW Chow, FRCS(Ed)⁶, Calvin SH Ng, MD⁷, Maggie HT Wang,
- PhD⁵, Zigui Chan, PhD⁸, Paul KS Chan, MD⁸, Albert M Li, MD^{1,2,3,4}, Renee WY
 Chan, PhD^{1,2,3,4}*
- 8
- 9 ¹ Department of Paediatrics, Faculty of Medicine, The Chinese University of Hong
 10 Kong.
- ²CUHK-UMCU Joint Research Laboratory of Respiratory Virus & Immunobiology,
- 12 Faculty of Medicine, The Chinese University of Hong Kong.
- ³Hong Kong Hub of Paediatric Excellence, The Chinese University of Hong Kong.
- ⁴Laboratory for Paediatric Respiratory Research, Li Ka Shing Institute of Health
- Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong KongSAR.
- ⁵ Jockey Club School of Public Health and Primary Care, Faculty of Medicine, The
- 18 Chinese University of Hong Kong.
- 19 ⁶Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese
- 20 University of Hong Kong.
- ²¹ ⁷ Division of Cardiothoracic Surgery, Department of Surgery, The Chinese University
- of Hong Kong.
- ⁸ Department of Microbiology, Faculty of Medicine, The Chinese University of Hong
- 24 Kong.
- 25
- [†]These authors contributed equally to this work.
- 27 *Corresponding Author
- 28

29 Corresponding Author:

- 30 Renee WY Chan, Assistant Professor
- 31 Address: Department of Paediatrics, 6/F, Lui Chee Woo Clinical Sciences Building,
- 32 Prince of Wales Hospital, New Territories, Hong Kong.

33 **Email:** reneewy@cuhk.edu.hk

34 Abstract

35

36 **Background**: Investigations of the natural viral interference effect between rhinovirus 37 (RV) and influenza virus (IV) were conducted in temperate regions. We conducted an 38 epidemiological study in Hong Kong, a major epicentre of influenza virus in the sub-39 tropical region. RV is the most prevalent respiratory virus year-round and causes 40 asymptomatic to mild symptoms while IV infection exerts a great burden of public 41 health. We aimed to examine the correlation of RV prevalence against IV activity. 42 Methods: Nasopharyngeal aspirates (NPA) collected from patients hospitalized in the 43 regional hospitals from 2015 to 2019 were examined for the presence of respiratory 44 viruses. The correlation of the monthly prevalence between all pairs of virus infection, 45 the co-infection rate and the temporal interference of RV and IV were tested. The 46 viral interference was validated in vitro by conducting sequential RV and IV infection 47 in the well-differentiated primary human airway epithelial cells. 48 Findings: A total of 112,926 NPA were evaluated, and the Enterovirus/RV was the 49 most prevalent respiratory virus detected. The negative correlation between EV/RV 50 and IVs prevalence was independent of age and meteorological factors. Co-infection 51 of EV/RV and IV was significantly less when compared with other virus pairs. Prior 52 exposure to RV inhibited the replication of influenza A, B and oseltamivir-resistance 53 stain *in vitro* and the inhibition is replication dependent. 54 Interpretation: Epidemiological surveillance and the sequential infection in vitro 55 suggested viral interference between EV/RV and IV operated at the population, 56 individual and cellular levels. 57 Funding: This study was supported by the General Research Fund (Ref: 24107017

and 14103119 to RWYC), Health and Medical Research Fund (Ref: COVID190112

- 59 to RWYC) and the Chinese University Direct Grant for Research (Ref: 2019.073 to
- 60 RWYC).

61 Introduction

62 Influenza virus (IV) confers substantial morbidity and mortality worldwide every year.

63 The existence of natural reservoirs of IV makes it impossible to be eradicated in64 humans.

65 Influenza vaccine is the classic preventive measure to attenuate disease severity. However, the viral antigenic drift may limit the duration of vaccine effectiveness,¹ 66 while the antigenic shift may result in the emergence of new strains.² Antivirals is 67 another prophylactic and therapeutic option with a limited effective time frame.³ 68 69 Moreover, antiviral resistant IV strains have been reported sporadically, with an 70 increasing number of oseltamivir-resistant influenza A (R-IAV) is being found.⁴ 71 Whether or not there is natural viral interference in counteracting the influence of IV 72 in the human population or individual levels is an interesting question to address. 73 Identifying novel interfering factors that confer temporal immunity against pan-74 influenza and other virulent viral infections would provide alternative options for 75 disease prevention and treatment.

76

77 Rhinovirus (RV), on the other hand, is the most frequent respiratory pathogen being detected throughout the year.⁵ However, it catches less attention in the public health 78 79 aspect as it generally causes mild and self-limiting symptoms, and sometimes it is asymptomatic in healthy individuals.⁶ Nevertheless, infants could have up to six to 80 81 eight RV infections per year, while adults could have around two to four episodes annually.⁷ Having RV infections repeatedly seems to be unavoidable as it comprises 82 83 more than 160 distinct genotypes. Among genotypes, they do not confer substantial immunity against each other.⁸ Intriguingly, though the prevalence of RV is high, the 84 85 epidemiology study on RV is uncommon due to its high genotypic diversity. The

86 enterovirus/rhinovirus (EV/RV) test was not included as a standard test in clinical
87 labs until recent years. In Hong Kong, it has become available in public hospitals
88 since September 2015.

89

90 With the advancement for the co-detection of viruses through multiplex PCR, 91 multiple population-wide surveillance programs suggested that seasonality of 92 respiratory viral infection is not only contributed by meteorological factors but also 93 the biological interactions among different viruses. The concept of viral interference, 94 a phenomenon in which a primary virus infection could transiently prevent or inhibit the secondary superinfecting virus,⁹ may also play an important role in influencing the 95 96 pattern of virus outbreaks. Multiple epidemiological analyses, including studies 97 performed in the United Kingdom and the United States, identified a negative interaction between the prevalence of IVs and RVs,^{10,11} and viral interactions operate 98 at multiple levels.¹² In the epidemiological part of this study, we investigated 99 100 correlation of virus prevalence and the temporal interference between RV and IV at 101 the population level and the chance of co-infection at individual level. We validated 102 this concept further by conducting sequential infection study in the differentiated 103 primary human nasopharyngeal epithelial cells (HNEC) and human bronchial 104 epithelial cells (HBEC) to elucidate the inhibitory effect in vitro.

105

106 Methods

107 **Study population and dataset.** Nasopharyngeal aspirates (NPA) were collected from 108 patients admitted to the six hospitals under the Hong Kong New Territories East 109 Cluster and were screened routinely for respiratory viruses from September 2015 to 110 December 2019. Multiplex real-time PCR were performed by Public Health

111 Laboratory Centre, Centre for Health Protection, Department of Health, Hong Kong. 112 The respiratory virus panel, including influenza A virus (IAV, with subtyping of H1 113 and H3), influenza B virus (IBV), influenza C (ICV), parainfluenza viruses 1-4 (PIVs), 114 enterovirus/rhinovirus (EV/RV), respiratory syncytial viruses (RSV) and adenovirus 115 (ADV). The test-negative samples were retained as part of the essential denominator 116 to reflect the prevalence in the community to address the fluctuation in sample size 117 over the study period. This virological data covered nine episodes of IV peaks of four 118 consecutive years. Samples with missing or uncertain entries were excluded (<1%). 119 This study was approved by the Joint Chinese University of Hong Kong – New 120 Territories East Cluster Clinical Research Ethics Committee (CREC: 2015.097 and 121 2019.120).

122

Meteorological data. We obtained the meteorological data including ambient temperature (°C) and mean relative humidity (%) measured at the central monitoring station run by the Hong Kong Observatory. The weekly averages of meteorological record were matched with the prevalence over the study period. As absolute humidity was showed to be associated with the respiratory infections,¹³⁻¹⁵ we employed actual vapour pressure (hPa) as a proxy of this humidity measure. The derivation of actual vapour pressure was based on Teten's formula,¹⁶

130
$$e = \frac{RH}{100} \times 6.105 \times \exp\left(\frac{17.27 \times TEMP}{237.7 + TEMP}\right)$$

where e, TEMP, and RH denote actual vapour pressure, ambient temperature, andrelative humidity respectively.

133

Cell lines. H1-HeLa (CRL-1958) and Madin-Darby canine kidney cells (MDCK,
CCL-34) were purchased from American Type Culture Collection. Cells were

cultured in minimal essential media with non-essential amino acids, 2mM Lglutamine supplemented with 1% penicillin and streptomycin, and 10% fetal bovine
serum. Both cell lines were maintained at 37°C and used for RV and IV virus
propagation and titration.

140

141 Virus preparation. RV-1B (VR-1645) and RV-A16 (VR-283PQ) were purchased 142 from ATCC and were propagated in H1-HeLa. RV-A16 is a major group RV utilizing 143 ICAM1 as the cellular receptor, and RV-1B belongs to the minor group utilizing 144 LDLR as the cellular receptor, were chosen for this proof-of-concept *in vitro* infection. 145 Seasonal IAV (H1N1 human isolate A/Oklahoma/447/2008), IBV (B/Hong 146 Kong/CUHK/12v033261/2012) and an oseltamivir-resistant H1N1 swine IAV 147 (A/Hong Kong/CUHK/09v071923/2009) were isolated from the NPA of patients and 148 were propagated using MDCK cells. Virus progeny was harvested when the 149 cytopathic effect (CPE) was observed. Virus titers were determined by a viral titration 150 assay.

151

152 Virus titration. H1-HeLa and MDCK cells were seeded on 96-well tissue culture 153 plates one day before the viral titration assay. Cells were washed once with PBS. 154 Virus samples or culture supernatants were titrated in serial half-log₁₀ dilutions with 155 the corresponding culture medium before adding the diluted virus to the cell plates in 156 quadruplicate. The highest viral dilution leading to CPE was recorded and the 50% 157 tissue culture infectious dose (TCID₅₀) was calculated using the Karber method. The 158 infectivity of RV and IV was monitored by the infectious viral load in the supernatant, 159 as quantitated by viral titration in H1-HeLa or MDCK cells, respectively.

160

161 Airway epithelial cell isolation and differentiation. Human nasopharyngeal 162 epithelial cells (HNEC) and bronchial epithelial cells (HBEC) were isolated from nasopharyngeal flocked swab and bronchial tissue as described ¹⁷. Briefly, cells were 163 164 seeded in a 6 well plate coated with human collagen IV and cultured with BEpiCM 165 (Sciencecell): Advanced DMEM (Life Technologies) 1:1 supplemented with HEPES, 166 PS, primocin, glutamax, B27, hydrocortisone, triiodothyronine (T3), epinephrine, N-167 acetyl-cysteine, nicotinamide, TGF^β inhibitor, BMPi, Rocki, FGF10, FGF7, IGF-1, 168 BSA and R-spondin 1 conditioned medium. Upon confluence, cells were dissociated 169 by TrypLE and seeded onto PureCol coated transwell with a cell density of 170 2×10^{5} cell/well in a 24-well format, and cultured in an air-liquid interface (ALI) using 171 differentiated PneumoCult ALI medium (StemCell) for at least 28 days before 172 infection experiments. Demographics of the donors were provided in **Supplementary** 173 Table 1.

174

175 Experimental design of the sequential RV-A16 and IV virus infection in vitro. 176 Primary HBECs and HNECs were washed with 125ul of PBS five times before 177 infection. Cells were exposed to infection regime 1) RV, 2) IV or 3) a prior RV 178 infection then a IV infection at 48 hpi of the initial RV inoculation at a multiplicity of 179 infection (MOI) of 0.01 (Figure 6A). In the infection step, 100ul of RV or sham 180 inoculum were added and allowed for virus attachment for 2 hours at 37°C. The 181 inoculum was discarded, and the cells were washed with PBS twice and the 182 basolateral compartment was replenished with 600ul of the medium. At 48 hours post 183 infection (hpi) of RV, cells were washed with PBS twice before secondary infection 184 of IAVs. The supernatant from the apical compartment of the transwell inserts were

185 collected at 2, 24 and 48 hpi for viral titers determination and gene expression186 analysis.

187

| 188 | RNA extraction and gene expression analysis. QIAGEN Viral RNA extraction kit |
|-----|--|
| 189 | and RNaeasy Kit were used according to the manufacturer's instructions for RNA |
| 190 | extraction followed by qPCR. Viral RNA and total RNA were reverse transcribed into |
| 191 | cDNA with a PrimerScript RT reagent Kit (Takara). mRNA expression was measured |
| 192 | by real-time PCR amplification with SYBR Premix Ex Taq II (Tli RNase H Plus) |
| 193 | (Takara) and an ABI Quant Studio 12K real-time PCR system (Applied Biosystems). |
| 194 | Absolute quantification of IAV matrix 1 gene was done with standard plasmids and |
| 195 | normalized by housekeeping gene GAPDH. Primers used in this study were: |
| 196 | GAPDH-F: GTCTCCTCTGACTTCAACAGCG; |
| 197 | GAPDH-R: ACCACCCTGTTGCTGTAGCCAA; |
| 198 | IAV-matrix gene-F: GGCATTTTGGACAAAKCGTCTA; |
| 199 | IAV-matrix gene -R: CTTCTAACCGAGGTCGAAACG |
| 200 | |

201 Statistical analysis

202 The association of the monthly prevalence between all pairs of virus infections was 203 tested using Spearman's rank correlation coefficients. To assess whether IV 204 prevalence was statistically associated with the evolution of the future values EV/RV 205 prevalence, the Granger causality test was conducted and the significant lagged week of IV prevalence was determined.¹⁸ To examine the association between EV/RV and 206 207 IV prevalence independent of meteorological effects at different lagged times, a 208 quasi-Poisson generalized additive model (GAM) was used to control the total 209 number of weekly collected samples (i.e. model offset), long-term trend, and seasonal

trend. The technical detail has been noted in the Supplementary File. The effect of EV/RV on IV prevalence was quantified using adjusted relative risk (ARR) along with its corresponding 95% confidence interval (CI). The reference value was set as its median value.

214

215 The likelihood of viral co-infection was computed by Fisher's exact test and logistic 216 regression after adjustment to age and gender. Age group stratification with toddlers 217 (age <2), preschool (age 2-5), school-age (age 6-17), adult (age 18-64) and elderly 218 (age >65) were segregated for regression analysis. Differences in influenza titers and 219 viral gene expression was compared at respective time points with or without prior 220 EV exposure using two-way ANOVA followed by *Bonferroni* post-test for multiple 221 comparisons. One sample t-test was used to compare the changes (\log_{10} transformed) 222 in IV titer with prior RV infection, with null hypothesis assuming no difference with 223 sham treated control cells isolated from the same individuals. All statistical tests were 224 performed using Graphpad version 9.2.0 and IBM SPSS Statistics. Differences were 225 considered statistically significant at p < 0.05.

226

227 Results

Opposing seasonality of EV/RV and IVs. A total of 112,926 NPA were included in this study. EV/RV was the most prevalent viral infection (Figure 1B), and it contributed a monthly positive rate of at least 8% throughout the study period (Figure 2, red line). IVs were the second most dominant viral group being detected (Figure 2, navy line). Combining IAV, IBV and ICV, reached up to 35% positive rate during flu season but remained low for the rest of the year. A strong seasonal pattern was observed in both EV/RV and IVs, with robust biannual peaks of EV/RV occurred

during spring and autumn, and one to two peaks of IV occurred in summers and
winters of Hong Kong, yet the onset, magnitude, duration and dominating subtypes of
the peaks varied extensively (Figure 2). A staggered pattern between EV/RV and IVs
has been observed in which the intensity of flu peaks was often higher after a low
EV/RV season. During the spring of 2017, the shortest period of EV/RV peak was
followed by an early outburst of IAV of the H3N2 subtype.

241

242 Negative correlation between the prevalence of EV/RV with IVs. Interactions 243 between viruses may be confounded by other factors such as the age of the subjects 244 and meteorological factors during sampling. In the current study, we analyzed the 245 virological data by age stratification (Figure 1C). EV/RV was the most prevalent in 246 those aged under 2 years old, while the median age of IAV and IBV positive cases 247 was significantly higher (11.19 and 7.84 years old, respectively) than that of EV/RV 248 (4.01 years old). Due to the variation of the influenza subtypes each year, IAV-H1, 249 IAV-H3, IBV and ICV were combined as IVs for regression analysis. Logistic 250 regression analysis revealed a significant negative correlation between the monthly 251 prevalence of EV/RV against IVs (-0.421, p < 0.01, Figure 3C, navy) but not with 252 other virus pairs, such as PIVs, RSV and ADV. Spearman's bivariate analysis showed 253 a similar result in which a significant negative correlation was identified between 254 EV/RV against total IVs or IAV (Table 1). Significant negative correlations between 255 the monthly IVs prevalence and PIV2 and PIV4 were though their intensities were not 256 as strong as that between IVs and EV/RV.

257

258 **Time series causality.** IV prevalence was significantly associated with the evolution 259 of EV/RV (p<0.001) and the effect of IV was highly significant at lag zero (p<0.001),

| 260 | indicating a non-lagged interference between IV and EV/RV as assessed by the |
|-----|--|
| 261 | Granger causality test. The disease-disease association at lag zero was further |
| 262 | examined via GAM analysis and a significant negative association between IV and |
| 263 | EV/RV was showed (Figure 4). The ARR of EV/RV was 0.652 (95% CI: 0.571 to |
| 264 | 0.745) when the prevalence of IV increased to 31.3% (i.e. 95^{th} percentile of IV), |
| 265 | whereas the ARR of EV/RV was 1.159 (95% CI: 1.079 to 1.244) when the prevalence |
| 266 | of IV decreased to 1.5% (i.e. 5 th percentile of IV), with a median reference value |
| 267 | (9.3%). |
| | |

268

Moreover, the negative relationship between EV/RV and IV was independent to meteorological variations from both ambient temperature & relative humidity and absolute humidity. After controlling the effect of temperature and relative humidity, the ARR of EV/RV was 0.654 (95% CI: 0.572 to 0.748) when the prevalence of IV was at its 95th percentile. An increase of lagged time of IV demonstrated a sinusoidal change in the ARR of EV/RV, highlighting a counteracting oscillation between the two infections (**Supplementary Figure 1**).

276

277 Reduced likelihood of EV/RV and IVs co-infection. Co-infection of respiratory 278 viruses is common in hospitalized patients. Overall, 9.1% (n=2,582) of the NPA 279 samples were co-detected with two or more respiratory viruses, and 59.8% of these 280 co-infection cases were contributed by EV/RV (n=1,545) (Figure 5A). Co-infections 281 were more common in children, in which more than 80% of cases were found in 282 paediatric patients with age under 18 (Figure 5B). Interestingly, the odds to have both 283 EV/RV-IVs detected in the same specimen was exceptionally low (OR=0.15) when 284 compared with 0.75 for EV/RV-PIVs, 0.54 for EV/RV-RSV and 0.94 for EV/RV-

- ADV co-detection using Fisher's Exact Test (**Figure 5C**). A further reduction in odds was observed between EV/RV and IVs after the adjustment of the confounding effect due to age and gender by binary logistic regression (**Figure 5D**).
- 288

Sequential infection of RV and IV in HBEC and HNEC. To address if viral interference between IV and RV occurs at the cellular level, a sequential infection was performed on well-differentiated human airway epithelial cells (**Figure 6A**). RV-A16 and RV-1B and seasonal IAV, IBV and R-IAV showed productive replication and achieved a 2-log₁₀ increase at 48 hpi. HBEC were susceptible to RV-A16 and RV-1B infection and replication without cytopathic changes, while IV infection led to obvious CPE at 48hpi (**Supplementary Figure 2**).

296

Suppression of IAV infection and replication with prior exposure to RV-A16 and RV-1B in HBEC and HNEC. Prior exposure to RV-A16, the IV replication was inhibited. The viral load was significantly inhibited with a mean reduction of 1.44 log₁₀ and 1.22 log₁₀ in HBECs and 2.95 log₁₀ and 2.58 log₁₀ in HNECs at 24 h and 48 h post influenza virus infection, respectively, compared with those exposed to sham treatment. (Figure 6B). A significant reduction in the normalized IAV matrix gene copies was also observed in both cell types (Supplementary Figure 2I).

304

Active RV replication is essential to exert viral interference. Heterogenicity in individual's susceptibility to RV was observed. HNECs derived from 4 out of 5 donors, and HBECs derived from 6 out of 9 donors supported productive replication of RV (**Supplementary Table 1 and Supplementary Figure 3**). Importantly, we found that the interference effect depended on the active replication of RV. The

inhibition effect to IAV infection was abolished in non RV-replicating cells. Using
ultraviolet-inactivated RV-A16 as the inoculum, we confirmed this observation again
and found that the UV-inactivated virus did not suppress the subsequent IVA and IVB
replication.

314

315 Suppression of IBV and oseltamivir-resistant IAV with prior exposure to RV-316 A16 and RV-1B in HBEC. The suppression by the prior exposure of RV-A16 was 317 not limit to IAV. A significant reduction of IBV (1.91 log₁₀, and 2.25 log₁₀ at 24hpi 318 and 48hpi, p < 0.05) and oseltamivir-resistant IAV strain (3.85 log₁₀ and 2.64 log₁₀ at 319 24 and 48hpi respectively, p < 0.01, Figure 6C) was observed in RV-A16 infected 320 cells compared with sham-exposed HBECs. Moreover, RV exposure protected HBEC 321 from IAV induced cell death. Extensive CPE was starting from 48hpi, while no CPE 322 was observed for at least 7 days if the cells were infected with RV-A16 before IVA 323 infection (Supplementary Figure 2C to 2H). To rule out if the observation is a 324 specific effect of RV-A16, the same experiment setting was carried out using RV-1B 325 in HBECs. RV-1B suppressed the IAV replication by $2.59 \log_{10}$ at 48hpi but not at an 326 earlier time point (Figure 6D). Taken together, our result supports that RV infection 327 attenuates the subsequent influenza replication in primary human respiratory 328 epithelial cells.

329

330 Discussion

The influenza virus exerts a great burden on the health system each year in terms of frequent medical visits, hospitalization and flu-related death. We demonstrated the viral interference between RV and IVs using epidemiological data and biological experiments, suggesting a broad protective role of EV/RV in inhibiting subsequent

335 IVs. We evaluated this interaction using the epidemiological data collected from 336 hospitalized patients from September 2015, when the EV/RV test was first introduced 337 as a routine test in the clinical settings, to December 2019, the last normal month 338 before the SARS-CoV-2 pandemic began. In this study, a total of 112,926 NPA 339 obtained from all ages were examined. The negative association between EV/RV and 340 IVs prevalence was independent of subject age and meteorological factors. Consistent with studies performed in different climatic parameters, ^{10,11} an interference effect in 341 342 population-level is suggested. We also demonstrated the competitive effect between 343 the two could also operate at the individual level as the likelihood of getting co-344 detection between EV/RV and IVs was exceptionally low compared with other virus 345 pairs. During these nine flu seasons in Hong Kong, it is intriguing to see that EV/RV 346 prevalence oscillated in a counteracting manner. For example year 2015, 2018 and 347 2019 represented the lowered EV/RV positive rate of winters (November to February 348 of the next year) within the study window were followed by some of the most intense 349 winter flu outbreaks. The opposite is true for the summer of 2018. While experiencing 350 the highest summer EV/RV prevalence within the period, the intensity of flu within 351 the same season was almost abolished. The magnitude of concurrent RV peak may 352 forecast the intensity of IVs in the same season which is beneficial for public health 353 management before flu outbreaks.

To convey the observation of viral interference from *in vitro* settings to the population level, a transmission study using animal models will be a choice. It has been shown that prior exposure to RV-1B can reduce the severity of mouse-adapted IAV PR8 in a dose-dependent manner. ¹⁹ In the same study, mice with a double-stranded RNA (dsRNA) mimic before IAV infection significantly reduce viral load. Aligned with our findings in cells that did not support RV replication and UV-inactivated RV, it has

been shown that UV-inactivated RV cannot induce antiviral cytokine responses.²⁰ The
lack of inhibitory effect to subsequent IAV infection suggested that active virus
replication within the host is required. Viral interference may be mediated by factors
such as IFNs, defective interfering particles, production of trans-acting proteases,
cellular factors, and nonspecific dsRNA.²¹ A recent finding from an *in vivo* mouse
model suggested that inhibition of IAV PR8 by RV depended on type I IFN signalling
pathway.²²

367

368 It has been shown that nonpharmaceutical interventions such as ethanol hand rub and 369 facemasks are not effective in controlling the transmission of non-enveloped EV/RVs 370 ^{23,24}. During the SARS-CoV pandemic, hospitalization and positive rate for detected 371 enveloped virus including IVs, PIVs and RSV were drastically reduced but that of EV/RV was less affected throughout 2020²⁵. Excluding the period of SARS-CoV-2 372 373 pandemic is necessary to address the interference effect in the community as the 374 implementation of social distancing measures and enhanced personal hygiene has a 375 great effect in suppressing the transmissibility of respiratory viruses. Using a similar 376 experimental design, our preliminary in vitro infection model suggested that prior 377 RV-A16 infection could suppress SARS-CoV-2 replication using HBEC 378 (Supplementary Figure 4). A recent finding suggested that the protective effect 379 conferred by prior EV exposure in respiratory cells is again due to the induction on 380 IFN-stimulated genes shared high consistency with our findings 26 .

381

In vitro infection using ALI differentiated cells and mathematical simulations also
 agree that RV has an interference effect against SARS-CoV-2 at multiple levels. ²⁷
 These results all point to the fact that EV/RV infection, which usually causes mild or

asymptotic infection in healthy individuals, may provide at least transient protective
effect against more virulent viral infections such as influenza and SARS-CoV-2.
Immunomodulatory effect due to mild EV/RV effect may serve as a novel antiviral
defense against emerging outbreaks when therapeutics are not available.
Understanding the molecular mechanism on how EV/RV triggering innate immunity
may shed light on novel prophylactics design against board range of viral infections.

391

392 **Limitations:** The viral interference window induced by RVs to IVs *in vitro* was up to 393 48 hours and the maximal duration is yet to define. We demonstrated that the 394 inhibitory effect was significant for at least 48 hours post influenza virus infection. 395 However, the exact durability of the inhibition exerted by RV was not thoroughly 396 assessed in this setting because of extensive cell death in the sham-treated cells 397 (Supplementary Figure 3H). Moreover, we did not investigate if the suppression of 398 IAV by RV relate to impairment of influenza virus receptor. Nevertheless, a previous 399 study showed that RV-A16 infection on HBEC did not alter the transcription of α 2-6-400 linked and α 2-3-linked sialyl-transferases, which are responsible producing the 401 relevant sialic acid receptor, thus the restriction on IVA is independent of the change in receptor availability.²⁸ Lastly, the action of competition between RV and IV by 402 403 adding the virus together at the same time point or prior infection of IV to subsequent 404 RV infection was not evaluated. The latter could not be evaluated in our human 405 primary respiratory epithelial cell culture, as the IV would cause a significant CPE 406 even at a low MOI.

407

408 Conclusion

- 409 The cumulative evidence suggests the occurrence of viral interference at the
- 410 population, individual and cellular level. The understudied role of RV in providing
- 411 the baseline immunity to influenza virus replication warrants further attention.

412 Acknowledgements

| 413 | We would like to acknowledge Professor Gillian M Air of the University of |
|-----|---|
| 414 | Oklahoma Health Sciences Center who provides IAV strain A/Oklahoma/447/2008 |
| 415 | H1N1 for the study; Drs Steffi X Long and Louisa LY Chan for culturing the human |
| 416 | primary epithelial cells the study; Ms Waii WY Yu for her assistance in the molecular |
| 417 | biology experiments. Drs Michael CW Chan and Dr Kenrie PY Hui for the SARS- |
| 418 | CoV-2 infection. |
| 419 | |
| | |

420 Authors contributions

- 421 Conception, experimental design, drafting the manuscript and interpretation: KPT,
- 422 MKCC and RWYC; Data Analysis: KPT, MKCC, JSCP, MHW, RWYC; Collection
- 423 of bio-specimen: JGST, SMWC, CSHN, ZC, PKSC, AML; Execution of experiment
- 424 and acquisition of data: KPT and JCSP. All authors reviewed and approved the final
- 425 manuscript.

426 **Reference**

- 427 Cao L, Lou J, Zhao S, et al. In silico prediction of influenza vaccine 1. 428 effectiveness by sequence analysis. *Vaccine* 2021; **39**(7): 1030-4. 429 2. Treanor J. Influenza vaccine--outmaneuvering antigenic shift and drift. N Engl 430 *J Med* 2004; **350**(3): 218-20. 431 3. Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for 432 healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9(9): 433 537-45. 434 4. Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and 435 changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United 436 Kingdom, winter 2010/11. Euro Surveill 2011; 16(5). 437 Rotbart HA, Hayden FG. Picornavirus infections: a primer for the practitioner. 5. 438 Arch Fam Med 2000; 9(9): 913-20. 439 Self WH, Williams DJ, Zhu Y, et al. Respiratory Viral Detection in Children 6. 440 and Adults: Comparing Asymptomatic Controls and Patients With Community-441 Acquired Pneumonia. J Infect Dis 2016; 213(4): 584-91. 442 7. Chen WJ, Arnold JC, Fairchok MP, et al. Epidemiologic, clinical, and 443 virologic characteristics of human rhinovirus infection among otherwise healthy 444 children and adults: rhinovirus among adults and children. J Clin Virol 2015; 64: 74-445 82. 446 8. Glanville N, Johnston SL. Challenges in developing a cross-serotype 447 rhinovirus vaccine. Curr Opin Virol 2015; 11: 83-8. 448 9. Henle W. Interference phenomena between animal viruses; a review. J 449 Immunol 1950; 64(3): 203-36. 450 10. Nickbakhsh S, Mair C, Matthews L, et al. Virus-virus interactions impact the 451 population dynamics of influenza and the common cold. Proc Natl Acad Sci USA 452 2019. 453 Wu A, Mihaylova VT, Landry ML, Foxman EF. Interference between 11. 454 rhinovirus and influenza A virus: a clinical data analysis and experimental infection 455 study. *Lancet Microbe* 2020; **1**(6): e254-e62. 456 Opatowski L, Baguelin M, Eggo RM. Influenza interaction with cocirculating 12. 457 pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key 458 role for mathematical modelling. *PLoS Pathog* 2018; **14**(2): e1006770. 459 13. Chong KC, Lee TC, Bialasiewicz S, et al. Association between meteorological 460 variations and activities of influenza A and B across different climate zones: a multi-461 region modelling analysis across the globe. *J Infect* 2020; **80**(1): 84-98. 462 14. Chong KC, Liang J, Jia KM, et al. Latitudes mediate the association between 463 influenza activity and meteorological factors: A nationwide modelling analysis in 45 464 Japanese prefectures from 2000 to 2018. Sci Total Environ 2020; 703: 134727. 465 Leung SY, Lau SYF, Kwok KL, Mohammad KN, Chan PKS, Chong KC. 15. 466 Short-term association among meteorological variation, outdoor air pollution and 467 acute bronchiolitis in children in a subtropical setting. *Thorax* 2021; **76**(4): 360-9. 468 16. Tetens O. Uber einige meteorologische Begriffe. Z Geophys 1930; 6: 297-309. 469 17. Chan RW, Chan MC, Nicholls JM, Malik Peiris JS. Use of ex vivo and in 470 vitro cultures of the human respiratory tract to study the tropism and host responses of 471 highly pathogenic avian influenza A (H5N1) and other influenza viruses. Virus Res 472 2013; 178(1): 133-45. 473
- 473 18. Granger C. Investigating Causal Relations by Econometric Models and Cross474 spectral Methods. *Econometrica* 1969; **37**(3): 424-38.

- 475 19. Gonzalez AJ, Ijezie EC, Balemba OB, Miura TA. Attenuation of Influenza A
- 476 Virus Disease Severity by Viral Coinfection in a Mouse Model. *J Virol* 2018; 92(23).
 477 20. Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus-
- 477 20. Bartlett NW, Walton RP, Edwards MR, et al. Mouse models of rhinovirus478 induced disease and exacerbation of allergic airway inflammation. *Nat Med* 2008;
- 478 induced disease and exacerbation 479 **14**(2): 199-204.
- 480 21. Kumar N, Sharma S, Barua S, Tripathi BN, Rouse BT. Virological and
- 481 Immunological Outcomes of Coinfections. *Clin Microbiol Rev* 2018; **31**(4).
- 482 22. Van Leuven JT, Gonzalez AJ, Ijezie EC, et al. Rhinovirus Reduces the
- 483 Severity of Subsequent Respiratory Viral Infections by Interferon-Dependent and 484 Independent Mechanisms. *mSphere* 2021; 6(3): e0047921.
- 485 23. Savolainen-Kopra C, Korpela T, Simonen-Tikka ML, et al. Single treatment 486 with ethanol hand rub is ineffective against human rhinovirus--hand washing with
- 487 soap and water removes the virus efficiently. *J Med Virol* 2012; **84**(3): 543-7.
- 488 24. Chen AP, Chu IY, Yeh ML, et al. Differentiating impacts of non-
- 489 pharmaceutical interventions on non-coronavirus disease-2019 respiratory viral
- 490 infections: Hospital-based retrospective observational study in Taiwan. *Influenza*
- 491 Other Respir Viruses 2021.
- 492 25. Centre for Health Protection HKSAR. Statistics on Laboratory Surveillance.493 2021.
- 494 26. Cheemarla NR, Watkins TA, Mihaylova VT, et al. Magnitude and timing of
 495 the antiviral response determine SARS-CoV-2 replication early in infection. *medRxiv*496 2021.
- 497 27. Dee K, Goldfarb DM, Haney J, et al. Human rhinovirus infection blocks
- 498 SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-499 19 epidemiology. *The Journal of Infectious Diseases* 2021.
- Proud D, Hudy MH, Wiehler S, et al. Cigarette smoke modulates expression
 of human rhinovirus-induced airway epithelial host defense genes. *PLoS One* 2012;
 7(7): e40762.
- 503 29. Essaidi-Laziosi M, Geiser J, Huang S, Constant S, Kaiser L, Tapparel C.
- 504 Interferon-Dependent and Respiratory Virus-Specific Interference in Dual Infections
- 505 of Airway Epithelia. *Sci Rep* 2020; **10**(1): 10246.
- 506

| p | IAV | IBV | ICV | PIV1 | PIV2 | PIV3 | PIV4 | RSV | ADV | IVs |
|-------|----------|---------|--------|--------|----------|--------|--------|----------|--------|-----------|
| EV/RV | -0-421** | 0.096 | -0.223 | 0.117 | 0.114 | 0.240 | 0.147 | 0.052 | 0.138 | -0-477*** |
| IAV | | -0.217* | -0.025 | 0.126 | -0.350** | -0.184 | 0.042 | 0.078 | -0.120 | - |
| IBV | | | 0.081 | -0.186 | -0.289* | 0.224 | -0.232 | -0.022 | -0.100 | - |
| ICV | | | | -0.147 | 0.277* | 0.138 | 0.025 | -0-426** | -0.125 | - |
| PIV1 | | | | | 0.038 | 0.275 | 0.415* | -0-172** | -0.051 | 0.047 |
| PIV2 | | | | | | 0.098 | -0.053 | -0.178 | -0.090 | -0-428** |
| PIV3 | | | | | | | 0.084 | -0.396* | -0.011 | -0.061 |
| PIV4 | | | | | | | | -0.047 | 0.059 | -0-109** |
| RSV | | | | | | | | | -0.032 | -0.044 |
| AdV | | | | | | | | | | -0.199 |

Table 1. Correlation of viral prevalence. Bivariate Spearman's cross-correlation coefficients between respiratory viruses using the monthly prevalence are shown. Asterisks indicate significance at $p<0.05^*$, $p<0.01^{**}$ and $p<0.001^{***}$. IVs in the last column indicates the sum of IAV, IBV and ICV, the cross-correlation within the IVs and IAV, IBV and ICV are therefore excluded from the analysis. Red and blue values indicate a negative and positive correlation, respectively.

| A. Demographics | | | | | |
|------------------------------------|--------|--------------------|------------|--|--|
| | Groups | No. of Patients | Percentage | | |
| | <2 | 17,025 | 15.08% | | |
| | 2-5 | 19,183 | 16-99% | | |
| Age Group | 6-17 | 11,570 | 10.25% | | |
| | 18-64 | 18,041 | 15.98% | | |
| | >65 | 47,107 | 41.71% | | |
| Gender | Female | 49,997 | 44.27% | | |
| | Male | 62,929 | 55.73% | | |
| B. Virological Readout (n=11 | 2,926) | | | | |
| | | No. of | Doroontogo | | |
| | | Patients | Fercentage | | |
| All negative | | 73,736 | 65.30% | | |
| Positively detected with | | 39,190 | 34.70% | | |
| Enterovirus/Rhinovirus | | 13,575 | 12.02% | | |
| Influenza A virus | | 9,831 | 8.70% | | |
| H1 subtype | | 3,757 | 3.34% | | |
| H3 subtype | | 6,081 | 5.38% | | |
| Influenza B virus | | 3,546 | 3.14% | | |
| Influenza C virus | | 381 | 0.34% | | |
| Parainfluenza 1 | | 1,325 | 1.17% | | |
| Parainfluenza 2 | | 766 | 0.68% | | |
| Parainfluenza 3 | | 2,468 | 2.19% | | |
| Parainfluenza 4 | | 1,363 | 1.21% | | |
| Respiratory Syncytial Virus | | 4,765 | 4.22% | | |
| Adenovirus | | 3,899 | 3.45% | | |



Figure 1. (A) Demographics of the patients included in the inpatient study from September 2015 to December 2019. (B) Virological readouts were obtained from all 112,926 NPA samples for the detection of virus infection by multiplex PCR. Subtyping of H1 and H3 were performed after positive IAV detection. (C) A violin plot showing the age distribution of virus infections from test-positive 39,190 NPA samples presents individual data as grey dots. The blue line shows the median age, and the red lines show the interquartile range.



Figure 2. Temporal dynamics of respiratory virus prevalence in the inpatient cohort from September 2015 to December 2019. Monthly prevalence of individual virus infections (left y-axis) with the respective number of tested samples showed in grey bars (right y-axis) throughout the study period. EV/RV = enterovirus/rhinovirus; IVs = influenza viruses; PIVs = parainfluenza viruses; RSV = respiratory syncytial viruses; ADV =adenovirus.



Figure 3: Negative correlation between the prevalence of EV/RV and IVs. (A) Prevalence of individual virus infections of different age groups is represented by the colour lines (left y-axis). The grey bar represents the number of samples tested in each group (right y-axis). (B) Prevalence of influenza subtypes (gradients of blue) compared to EV/RV (red) across the five-year study period. Typical influenza season (December to March, July to August) in Hong Kong is shaded in grey. (C) Logistic regression between the prevalence of EV/RV with other viruses with 95% CI marked in dotted lines. Significant negative correlation (-1.596 \pm 0.3110, *p*<0.001*** with R² = 0.3123) was identified only between EV/RV and IVs.



Figure 4. Adjusted relative risks (ARRs) with 95% confidence interval on EV/RV against IV prevalence. The estimated ARRs without controlling meteorological effects, with ambient temperature plus relative humidity controlled, and with actual vapor pressure adjusted are expressed as blue, red, and green colors respectively. Median IV prevalence was used as the reference value for comparison.

В

| 1 | |
|---|---|
| F | ١ |

| Viruses | Sample with >1 viruses detected | Sample detected with sole virus | Co- detection rate |
|---------|--|--|--------------------------|
| EV/RV | 1,545 | 13,575 | 11.38% |
| IAV | 627 | 9,831 | 6.38% |
| IBV | 206 | 3,546 | 5.81% |
| ICV | 168 | 381 | 44.09% |
| PIV1 | 174 | 1,325 | 13.13% |
| PIV2 | 150 | 766 | 19.58% |
| PIV3 | 388 | 2,468 | 15.72% |
| PIV4 | 496 | 1,363 | 36.39% |
| RSV | 663 | 4,765 | 13.91% |
| ADV | 894 | 3,899 | 22.93% |
| Overall | 2,582 | 39,190 | 2.29% |





С

| Virus pair | Expected | Observed | OR (95% CI) | |
|--------------|----------|----------|--------------------|-----|
| EV/RV – IVs | 1644 | 310 | 0.15 (0.13 - 0.17) | *** |
| EV/RV – PIVs | 701 | 546 | 0.75 (0.68 – 0.82) | *** |
| EV/RV – RSV | 573 | 331 | 0.54 (0.48 – 0.60) | *** |
| EV/RV – Adv | 469 | 444 | 0.94 (0.85 – 1.04) | ns |
| IVs – PIVs | 706 | 252 | 0.32 (0.28 – 0.36) | *** |
| IVs – RSV | 577 | 134 | 0.20 (0.17 – 0.24) | *** |
| IVs – Adv | 472 | 198 | 0.38 (0.33 – 0.44) | *** |
| PIVs – RSV | 246 | 136 | 0.52 (0.45 – 0.63) | *** |
| PIVs – Adv | 201 | 210 | 1.05 (0.91 – 1.21) | ns |
| RSV – Adv | 165 | 104 | 0.61 (0.54 – 0.74) | *** |

D

| | | RV prevalence | | IVs prevalence | |
|--------------|---------|----------------------|-----|----------------------|-----|
| Variables | Group | Adjusted OR (95% CI) | | Adjusted OR (95% CI) | |
| Gender | Female | 1 | | 1 | |
| | Male | 1.16 (1.12 – 1.21) | *** | 0.92 (0.88 – 0.95) | *** |
| Age Group | < 2 | 1 | | 1 | |
| | 2 - 5 | 1.32 (1.25 – 1.39) | *** | 2.16 (2.03 – 2.30) | *** |
| | 6 – 17 | 0.66 (0.62 - 0.70) | *** | 1.81 (1.69 – 1.94) | *** |
| | 18 – 64 | 0.20 (0.19 - 0.22) | *** | 0.65 (0.61 – 0.70) | *** |
| | > 65 | 0.16 (0.15 – 0.17) | *** | 0.46 (0.43 – 0.49) | *** |
| Co-detection | IVs | 0.091 (0.081 – 0.10) | *** | - | - |
| | RV | - | - | 0.091 (0.081 – 0.10) | *** |
| | PIVs | 0.34 (0.31 – 0.38) | *** | 0.20 (0.17 – 0.23) | *** |
| | RSV | 0.22 (0.21 – 0.24) | *** | 0.12 (0.10 - 0.14) | *** |
| | Adv | 0.39 (0.35 - 0.43) | *** | 0.19 (0.88 - 0.95) | *** |

Figure 5. Co-infection statistics. (**A**) Rate of co-detecting more than one respiratory virus in different respiratory virus infection. The number of NPA samples detected with more than one pathogen detected was divided by the total number of the sample test-positive with the agent listed in each row. (**B**) Breakdown of co-infection cases according to age group. (**C**) The odd ratio of EV/RV and IVs co-infection with other respiratory pathogens using Fisher's exact test with null hypothesis assuming the likelihood of individual infection events were not interrelated (**D**) Logistic regression analysis of EV/RV and IV infection after adjustment to gender and age group with the same adjustments.



Figure 6. RVs suppress subsequent IVs infection in vitro. (**A**) Experimental plan of the model. Fully differentiated ALI cultures were first infected (or sham-treated) with RVs for 2 days, followed by secondary infection of IVs. Supernatant and cell lysates were collected at 2, 24 and 48 hours post infection (hpi) for determination of viral load and gene expression. (**B**) Suppression of IVA titers with prior RV-A16 infection in HBEC (n=9) and HNEC (n=5). Y-axis represents the difference in titer in RV exposed to the sham-treated cells. (**C**) Suppression of IVB and oseltamivir-resistance stain of IVA (R-IVA) in HBEC with prior RV-A16 exposure. (**D**) Suppression of seasonal IVA with prior RV-1B infection in HBEC. Error bars showing the SEM of means and asterisks indicating significance of $p<0.05^*$, $p<0.01^{**}$ and $p<0.001^{***}$ compared with sham treatment as examined by one-sample t-test.